ModeX Therapeutics Inc, announces that the first participant has been dosed in the phase I trial (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate being developed alongside Merck, referred to as MSD outside the U.S. and Canada...
Roche announced that its complete slide imaging system, Roche Digital Pathology Dx, has obtained an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA). This approval alters the one Roche obtained on June 14, 2024, for Ro...
Increased investment in public healthcare, incentives for research and development, and tax breaks for additional life-saving medications are among the key demands of executives in the pharmaceutical and hospital sectors as they approach the...
US pharmaceutical giant Eli Lilly and Company announced that it intends to set up a new global capability center in Hyderabad. The organization plans to hire over 1,000 to 1,500 highly skilled individuals, including technology engineers and data...
The US Food and Drug Administration (FDA) released a draft guidance in collaboration with the Office for Human Research Protections that, once finalized, will offer suggestions for incorporating tissue biopsies into clinical trials. The draft...
Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405...
Pharmaceutical firm Lupin Ltd has stated that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Pithampur Unit-1 manufacturing facility, which produces both APIs and...
Novo Nordisk A/S and Valo Health, Inc. announced they have established a broader agreement to research and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease, utilizing Valo’s vast human dataset and AI-driven...
Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical firm leveraging innovative discovery technologies to reveal high-value, traditionally undruggable targets and create small molecule precision therapeutics for severe cancers and...
Dizal, a biopharmaceutical firm dedicated to creating innovative therapies for cancer and immunological disorders, revealed that the U.S. Food and Drug Administration (FDA) has accepted and assigned priority review to the company's New Drug...
, CDSCO.jpg)
